林业发展局批准Novo Nordisk的口服Wegovy, 这是美国第一个GLP-1减重药丸, 于2026年1月发射。 The FDA approved Novo Nordisk’s oral Wegovy, the first U.S. GLP-1 weight-loss pill, for launch in January 2026.

美国林业发展局批准了诺沃·诺迪斯克(Novo Nordisk)对Wegovy(Wegovy)的口头版本, 这是美国首个GLP-1减肥药丸, The U.S. FDA approved Novo Nordisk’s oral version of Wegovy, the first GLP-1 weight-loss pill in the U.S., marking a major milestone in obesity treatment. 每天一次的药片从每月149美元开始,定于2026年1月初推出,目的是帮助肥胖或超重的成年人及相关条件减肥和减少心血管风险。 The once-daily tablet, starting at $149 per month, is set for launch in early January 2026 and aims to help adults with obesity or overweight and related conditions lose weight and reduce cardiovascular risks. 通过该批准,诺沃诺迪斯克在竞争对手Eli Lilly的竞争中获得了先进优势,该公司的口服药物orforglipron预计将在2026年之前推出. The approval gives Novo Nordisk a first-mover advantage over rival Eli Lilly, whose oral drug orforglipron is expected by 2026. 该公司扩大了生产和担保协议的范围,通过Medicare、Medicaid和TrumpRx方案改善准入。 The company has expanded production and secured agreements to improve access through Medicare, Medicaid, and the TrumpRx program. 欧洲和美国的贸易份额上升了7%至10%,尽管今年在供应问题和竞争中股票仍然在下降45%以上。 Shares rose 7% to 10% in European and U.S. trading, though the stock remains down over 45% this year amid supply issues and competition. 分析家预测,该药丸可以捕捉到日益增长的重量损失市场的一大部分,但长期有效性和病人的摄入率仍有待观察。 Analysts project the pill could capture a significant share of the growing weight-loss market, but long-term effectiveness and patient uptake remain to be seen.